04.18.24 -- Designing Highly Agile Bio/Pharma Manufacturing Facilities

Accelerating the production of your viral vector-based therapy requires understanding the strategies and cost-efficiencies available to address the viral vector manufacturing shortage.

Developing a placebo for an injectable drug requires consideration of the formulation’s impact in trials, chemistry and physical details, ethical concerns, and regulatory compliance.

This handbook is intended to assist laboratory and manufacturing plant scientists and engineers in accurately selecting and maximizing the performance of aqueous cleaners and systems.

Explore compelling evidence that suggests Organ-on-a-Chip technology offers a far more reliable means of predicting drug toxicity than conventional animal models.

Understand the challenges and limitations of the blue dye test and see how the sensitivity of the blue dye test compares to other methods based on a comprehensive study.

Early-stage development is an iterative process, continuously generating new data and insights to optimize the product based on emerging knowledge.

Examine challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.

For R&D and PD applications, closed, single-use systems can protect against both biological and cross-contamination, saving valuable research time and money.

As we balance the time-to-market and risk for novel therapies, we must anticipate changing needs for combination device development, highlighting the technological paradigm shift.

Explore a real-world example of how a dynamic and growing CDMO implemented a lab management system to improve efficiency and data integrity for their quality control sample management workflows.

Conventional agitators are unable to create the fluid circulation necessary to disperse 4%+ powdered CMC dispersions. The consequence of insufficient agitation is the formation of non-dispersed lumps.

Explore the design of dissolution media to support biopredictive dissolution testing and a method for selecting practical, physiologically relevant media based on drug, formulation, and GI fluid properties.

Learn how CAI helped a company rescue a failing CQV project and create more efficient Vaporized Hydrogen Peroxide Material Air Lock (VHP MAL) Loads to enhance operational efficiency.

Discover how a solvent-free alternative for the production of amorphous solid dispersions (ASDs) not only improves manufacturability but also reduces the carbon footprint of ASD manufacturing.

Lonza has further improved its platform process with the creation of engineered plasmids that afford significantly higher titers and productivity levels compared to standard systems.